NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is a prestigious journal published by SPRINGER, focusing on the dynamic fields of pharmacology and toxicology. With an ISSN of 0028-1298 and an E-ISSN of 1432-1912, this esteemed publication has been a staple in the scientific community since its inception in 1969, continuing to wield influence with a convergence of research that reaches through 2024. Ranked in the Q2 category for both medicine and pharmacology, it stands at an impressive 111th out of 313 in the Scopus rankings for pharmacology, reflecting its significant impact in the field. Though not offering open access, the journal remains a vital resource for researchers, professionals, and students seeking to explore groundbreaking studies and advancements in pharmacological science. With its high standards and comprehensive coverage, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is essential reading for those dedicated to understanding the mechanisms of drug action and the complexities of therapeutic interventions.

PSYCHOPHARMACOLOGY is a leading peer-reviewed journal specializing in the field of pharmacology, specifically focusing on the effects of drugs on behavior, cognition, and emotion. Published by Springer, this esteemed journal has established itself as a pivotal resource for researchers and professionals since its inception in 1959, maintaining its relevance and rigor in the ever-evolving landscape of psychopharmacological research. With an impressive impact factor and ranking in the top quartile (Q1) of the Pharmacology category in 2023, it consistently publishes high-quality studies that contribute to both academic inquiry and clinical practice. The journal's scope includes original research, theoretical papers, and reviews, fostering a multidisciplinary dialogue among psychologists, psychiatrists, pharmacologists, and neuroscientists. As the field of psychopharmacology continues to grow, PSYCHOPHARMACOLOGY remains dedicated to disseminating innovative findings, operationalizing complex concepts, and enhancing the understanding of drug mechanisms and their implications for mental health. This commitment to excellence positions PSYCHOPHARMACOLOGY as an indispensable tool for those seeking to advance their knowledge and research in pharmacology.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

Advances in Pharmacology and Pharmacy is a pioneering journal devoted to the dissemination of cutting-edge research in the fields of pharmacology and pharmaceutical sciences. Published by Horizon Research Publishing, this peer-reviewed journal boasts a commitment to advancing knowledge and innovation, making it an essential resource for researchers, industry professionals, and students alike. With an ISSN of 2332-0036 and an E-ISSN of 2332-0044, it provides a platform for high-quality research articles that explore new therapeutic approaches, drug development strategies, and the regulatory aspects of pharmaceutical science. Although currently lacking a formal impact factor, the journal's emphasis on open access ensures that articles are widely available, promoting the sharing of valuable insights and collaborative efforts in the scientific community. Located at 506 N Garfield Ave, Ste 210, Alhambra, CA 91801, the journal welcomes contributions from diverse areas within pharmacology and pharmacy, reinforcing its significance as a vital resource in the ever-evolving landscape of pharmaceutical research.

PHARMACEUTICAL BIOLOGY, published by Taylor & Francis Ltd, is a prominent open-access journal that has been a cornerstone of research in the life sciences since its convergence in 1961. With a strong focus on Complementary and Alternative Medicine, Pharmaceutical Science, and Drug Discovery, this journal is dedicated to disseminating groundbreaking research that intersects pharmaceuticals and biology. Acknowledged for its rigorous peer-review process, it holds a prestigious Q1 ranking in Pharmaceutical Science and exemplifies the commitment to quality and impact in the field, boasting an impressive Scopus rank of #14/105 in the complementary and alternative medicine category. Researchers keen on advancing their knowledge in these fields will find PHARMACEUTICAL BIOLOGY an invaluable resource, offering accessibility since its shift to open access in 2017. This journal presents a platform for innovative studies that contribute to the evolving understanding of pharmaceutical applications and biological interactions, serving as an essential hub for researchers, professionals, and students alike.

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.